Lantheus (LNTH)
(Delayed Data from NSDQ)
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$112.50 USD
+0.54 (0.48%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $112.50 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Exact Sciences (EXAS) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Zacks Value Trader Highlights: Lantheus Holding, Matador Resources, Magnolia Oil & Gas, UFP Industries and Terreno Realty
by Zacks Equity Research
Lantheus Holding, Matador Resources, Magnolia Oil & Gas, UFP Industries and Terreno Realty are part of the Zacks Value Trader blog.
How to Find the Next Stock Market Leaders
by Tracey Ryniec
The tech bull is over. What will replace it?
Elevance Health (ELV) Tops on Q4 Earnings, Hikes Dividend
by Zacks Equity Research
Elevance Health's (ELV) fourth-quarter earnings gain on solid premiums from its Medicaid business. Management approves a quarterly dividend hike of 16%.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Lantheus Holdings (LNTH) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Lantheus Holdings (LNTH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How Much Upside is Left in Lantheus Holdings (LNTH)? Wall Street Analysts Think 83.92%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 83.9% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Lantheus Holdings (LNTH) Crossed Above the 50-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Surmodics (SRDX) Stock Skids 32% on Negative Regulatory Update
by Zacks Equity Research
Surmodics' (SRDX) SurVeil drug-coated balloon candidate receives additional data requests from the FDA.
Why You Should Hold Molina Healthcare (MOH) in Your Portfolio
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth on the back of a growing customer base within its Government business. Acquisitions and cost-saving measures also aid the health insurer.
Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?
by Zacks Equity Research
Here is how Aurora Cannabis Inc. (ACB) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
UnitedHealth (UNH) Unit Ties Up to Boost Care in Two U.S. Regions
by Zacks Equity Research
UnitedHealth Group's (UNH) subsidiary Optum aims to advance organizational efficiencies of Owensboro Health and bring about better health outcomes in western Kentucky and southern Indiana.
Lantheus Holdings (LNTH) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Lantheus Holdings (LNTH) closed the most recent trading day at $48.48, moving -0.94% from the previous trading session.
Teladoc (TDOC) Unveils App to Simplify Whole-Person Care
by Zacks Equity Research
Teladoc Health (TDOC) launches a digital app that will provide a broad range of TDOC's services to cater to the whole-person health needs of members.
Down -8.54% in 4 Weeks, Here's Why You Should You Buy the Dip in Lantheus Holdings (LNTH)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Lantheus Holdings (LNTH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Community Health (CYH) Sells Hospital, Renews Health Net Tie-Up
by Zacks Equity Research
Community Health (CYH) announces the divestiture of its West Virginia hospital and the expansion of its alliance with Health Net, thereby undertaking initiatives to boost business prospects.
Down -21.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Lantheus Holdings (LNTH)
by Zacks Equity Research
Lantheus Holdings (LNTH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is Lantheus (LNTH) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Lantheus Holdings (LNTH) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.
3 Medical Stocks Creating Wealth Despite Macro Challenges
by Indrajit Bandyopadhyay
Here we discuss three stocks - CAH, LNTH and TMDX - that have been creating wealth for their investors in 2022 as several competitors faltered amid macro challenges. Will the trend continue?
Lantheus Holdings (LNTH) Loses 10.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Lantheus Holdings (LNTH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Is RxSight (RXST) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how RxSight, Inc. (RXST) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Should SPDR S&P 600 Small Cap ETF (SLY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SLY
Wall Street Analysts Believe Lantheus Holdings (LNTH) Could Rally 64%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 63.9% in Lantheus Holdings (LNTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
3 Medical Products Stocks Navigating Industry Challenges (Revised)
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. QDEL, LNTH and TGTX are well-poised to gain from the favorable factors.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.